397 related articles for article (PubMed ID: 8283587)
21. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
22. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?
Lopez AS; Guris D; Zimmerman L; Gladden L; Moore T; Haselow DT; Loparev VN; Schmid DS; Jumaan AO; Snow SL
Pediatrics; 2006 Jun; 117(6):e1070-7. PubMed ID: 16740809
[TBL] [Abstract][Full Text] [Related]
23. The cost-effectiveness of varicella vaccine programs for Australia.
Scuffham PA; Lowin AV; Burgess MA
Vaccine; 1999 Oct; 18(5-6):407-15. PubMed ID: 10519929
[TBL] [Abstract][Full Text] [Related]
24. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
Lieu TA; Ray GT; Black SB; Butler JC; Klein JO; Breiman RF; Miller MA; Shinefield HR
JAMA; 2000 Mar; 283(11):1460-8. PubMed ID: 10732936
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
Bonanni P; Boccalini S; Bechini A; Banz K
Vaccine; 2008 Oct; 26(44):5619-26. PubMed ID: 18723062
[TBL] [Abstract][Full Text] [Related]
27. Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan.
Tseng HF; Tan HF; Chang CK
Southeast Asian J Trop Med Public Health; 2005 Nov; 36(6):1450-8. PubMed ID: 16610647
[TBL] [Abstract][Full Text] [Related]
28. Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland.
Heininger U; Pillsbury M; Samant S; Lienert F; Guggisberg P; Gani R; O'Brien E; Pawaskar M
Pediatr Infect Dis J; 2021 Jun; 40(6):e217-e221. PubMed ID: 33872276
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of the routine childhood immunization program in the United States, 2009.
Zhou F; Shefer A; Wenger J; Messonnier M; Wang LY; Lopez A; Moore M; Murphy TV; Cortese M; Rodewald L
Pediatrics; 2014 Apr; 133(4):577-85. PubMed ID: 24590750
[TBL] [Abstract][Full Text] [Related]
30. Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.
Holl K; Sauboin C; Amodio E; Bonanni P; Gabutti G
BMC Public Health; 2016 Oct; 16(1):1103. PubMed ID: 27769206
[TBL] [Abstract][Full Text] [Related]
31. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination.
Hanslik T; Boëlle PY; Schwarzinger M; Carrat F; Freedberg KA; Valleron AJ; Flahault A
Vaccine; 2003 Sep; 21(25-26):3614-22. PubMed ID: 12922090
[TBL] [Abstract][Full Text] [Related]
32. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
33. Clinical and economic considerations of vaccination against varicella.
Strassels SA; Sullivan SD
Pharmacotherapy; 1997; 17(1):133-9. PubMed ID: 9017774
[TBL] [Abstract][Full Text] [Related]
34. Impact of varicella vaccination on health care utilization.
Zhou F; Harpaz R; Jumaan AO; Winston CA; Shefer A
JAMA; 2005 Aug; 294(7):797-802. PubMed ID: 16106004
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of varicella vaccination programs: an update of the literature.
Rozenbaum MH; van Hoek AJ; Vegter S; Postma MJ
Expert Rev Vaccines; 2008 Aug; 7(6):753-82. PubMed ID: 18665775
[TBL] [Abstract][Full Text] [Related]
36. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of influenza vaccination of healthy children.
Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
[TBL] [Abstract][Full Text] [Related]
38. Costs and benefits of routine varicella vaccination in German children.
Beutels P; Clara R; Tormans G; Van Doorslaer E; Van Damme P
J Infect Dis; 1996 Nov; 174 Suppl 3():S335-41. PubMed ID: 8896542
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of vaccination strategies in adults without a history of chickenpox.
Smith KJ; Roberts MS
Am J Med; 2000 Jun; 108(9):723-9. PubMed ID: 10924649
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy.
Gialloreti LE; Divizia M; Pica F; Volpi A
Herpes; 2005 Oct; 12(2):33-7. PubMed ID: 16209858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
